Introduction
Gamma-hydroxybutyrate (GHB) is an endogenous compound found in the mammalian (Roth and Giarman, 1970) and human (Doherty et al., 1976) brains. Rubin and Giarman (1947) noted that gamma-.butyrolactone (GBL), a GHB congener, suppressed muscle activity in mice. Later, GBL was found to be metabolized in the liver to GHB, a central nervous system (CNS) active compound (Rubin and Giarman, 1947; Roth and Giarman, 1966; Fishbein andBessman, 1966; Roth et al., 1967) . Laborit et al. (1960 Laborit et al. ( , 1961 were the first to note GHB's anesthetic properties which led to its clinical use in Europe. Since that time there have been numerous investigations into the mechanism of action of GHB. Some early investigations have suggested that GHB may act through the gamma-aminobutyric acid (GABA) system (Roth and Nowycky, 1977; Stock et al., 1973) , while others (alpe et al., 1977) have reported that GHB's effects are independent of GABA mechanisms. GHB's possible relationship to sleep (Marmelak et al., 1977) and Huntington 's Chorea (Ando et al. , 1979) continue to be actively investigated. Snead et al. (1976) reviewed the correlations between blood and CSF levels and seizure activity on EEG in cats. Similar EEG patterns were noted in rats (Godschalk et al., 1977) .
Of great interest in the relationship of GHB and psychosis are the experiments concerning GHB's effect on the central neurotransmitter systems. GHB inhibits the firing-rate of dopaminergic neurons (Nowycky and Roth, 1979; alpe and Koella, 1979; Roth et al., 1973; Walters et al., 1972) in the CNS. This inhibition of dopamine-firing has been found to produce biochemical effects similar to those of electrolytic axotomy (Anden and Stock, 1973; Walters et al., 1973) . GHB has been found to increase brain dopamine (DA) (intracellular), presumably due to its ability to block impulse flow and DA release but has no effect on steady state levels of norepine· phrine (NE) (Gessa et al., 1966; Spano et al., 1971 ; Aghajanian and Roth, 1970; Roth and Surh, 1970) . Comprehensive reviews on the pharmacological and biochemical properties of GHB have been published recently (Walters and Roth, 1977; Snead, 1977) .
Having found differential effects of GHB on dopaminergic tracts in the limbic system, compared to striatal tracts (Ljundahl and Fuxe, 1975; Fuxe et al., 1977) , some investigators then suggested that the drug should be tried in schizophrenie patients (Walters and Roth, 1977; Fuxe et al., 1977 , van Kammen, 1977 . According to the DA hypothesis of schizophrenia, drugs that would decrease DA activity, particularly in the mesolimbic DA tract, could have antipsychotic effects (van Kammen, 1979 ; Meltzer and Stahl, 1976; Stevens, 1975) . GHB has been tried in some neurologie disorders in which DA presumably plays a role, such as Huntington's Chorea (McGeer et al., 1977 ), Parkinson's Disease and the muscle cramps of cerebral palsy (van Woert et al., 1975) . Some studies have noted that GHB is helpful in decreasing anxiety and agitation in some subjeets (DuCovedic et al., 1964; Dannon-Boileau et al., 1962) . Tanaka et al. (l966) administered GHB or GBL nonblind to 248 psychiatrie patients, 48 of whom suffered from ehronie sehizophrenia. Most improvement was seen in hebephrenies (5/7) and eatatonies (6O%) (number ofpatients not given). Qnly two ofsix schizophrenie patients with hallucinations and delusions improved. The present study was undertaken to evaluate, under doubleblind, plaeebocontrolled eonditions, the therapeutie claims for GHB on the symptoms of seven schizophrenie patients and, also, to further examine the DA hypothesis of sehizophrenia. Similarly, we evaluated high-dose diazepam in a small group of schizophrenie patients (Jimerson et al., sub- mitted for publieation).
Methods
Seven schizophrenic patients (3 males and 4 females) who were diagnosed with the RDC criteria of Spitzer et. al. (1978) and with at least four symptoms (range 4-10; means 7) ofthe International Pilot Study of Schizophrenia (IPSS) (Corpenter et al., 1973) participated in the study (Table 1) . Patients gave written informed consent and, in most cases, so did a member of their families. All patients were physicaUy healthy and adhered to a controlled monoamine diet. GHB administration was preceded by at least a 10-day placebo period and followed by a placebo period of 10 days. Neither patients nor staff were aware of when the trial started as there was no change in the number or charaeteristics orthe capsules. The beginning dose was 2 grams/day in five equally divided doses and was increased approximately every four days until a maximum dose of 8-16 grams was reached. The drug triallasted an average of 23 days (range 10-29 days). Behavior and movement disorders were assessed daily. Global psychosis ratings (modified Bunney-Hamburg Scale) (Bunney and Harnburg, 1963) were obtained daily by the nursing staff and weekly by the psychiatrists who were blind to the medication administration. Furthermore, the psychiatrists completed the Brief Psychiatric Rating Scale (BPRS) to evaluate each patient weeldy. Both groups entered their observations into the medical charts. Weekly, clinicallaboratory studies were performed (CBC, liver funetion, renal funetion, electrolytes and thyroid function). Blood levels of GHB were drawn at various doses during the trial one hour after the lust dose in the morning. GHB levels were measured by the spectrophotometric method, with a modification of the Hestrin assay by one of us (R.H.R.) (Hestrin, 1948; Guidotti and Balloti, 1970) .
Fill. 2 Individual double-blind psychosis ratings by the nursing staff. The data are presented as J.day running means. Each patient had been drug-free at 1east 2 weeks prior to each lP before the beginning of GHB treatment. Shaded areas indicate time of aetual GHB treatment. GHB was administered in divided doses five times each day. (Post et al., 1979) . Center: Platelet MAO activity: MAO is expressed as a corrected value for gender (see Method,) thus the maen value in normals is zero. Right: EP amplitude/intensity slope. The mean value in 95 normals was 0.69: 90th percentile 1.98 and 10 percentile -0.60. .!.
Tab. 1 Demographie and c1inical data. RDC Dx = research diagnostic criteria (Spitzer et al., 1978) ; Baseline lumber punctures (LP's) were obtained on a11 patients. Probenecid LP's were obtained on four patients before and during GHB treatment. Probenecid was administered in four divided doses (100 mg/kg) over an 18-hour period prior to the LP. LP's were performed with patients in the lateral decubitus position between 8:30 and 9:00 a.m. fo11owing nine hours of bed rest (van Kammen and Stern berg, 1980) . 3-Methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) were measured with mass spectophotometry (van Kammen and Stern berg, 1980) . Fo11owing the probenecid LP, which took place between 2:30 and 3:00 p.m., patients who experienced nausea or vomiting as a side effect of probenecid were given trimethobenzamine. During a drug-free period prior to the LP, pI~telet MAG activity was measured using benzylamine tagged with C as substrate (Murphy et al., 1976) . The MAG activity value used in this study was corrected for gender differences by subtracting the mean MAG for each sex from two large comparison groups to a110w combining of male and female subjects (males: 11.04 ± .29, N =348 and females: 13.29 ± .29, N =332) (Murphy et al., 1976) . Average evoked potentials (EPs) to four intensities of light were recorded as described elsewhere (Buchsbaum, 1978) . Each patient in this drug trial underwent EP testing before receiving the drug. The results are reported as the amplitude/intensity slope for Vertex PlOO component which has been postulated to separate a group of "augmenters" (stimulus intensity augmenters) from "reducers" (stimulus intensity reducers) .
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week after GHB. The nurses' global psychosis ratingsagree with the ratings by the psychiatrists using the BPRS items indicative of psychosis.
In an attempt to find discriminating characteristics among the two responders and the other patients, CSF HVA, platelet MAO activity and EP. were examined in relationship to change in psychosis. As can be seen in Fig. I , the responders had a higher mean HVA before the trial. Probenecid LP's prior to and during GHB treatment (obtained in 4/7 patients) revealed a slight decrease on drug for the mean HVA of the group. However, the two responders showed HVA values moving in opposite directions during GHB treatment. CSI'-MHPG was not changed significantly by GHB either (not shown). The platelet MAO values (corrected for sex) are displayed in Fig. 1 and show the mean value for the responders to be lower than for the nonresponders. The data in Fig. 1 show that the two responders were marked augrnenters on the EP measure prior to the GHB trial. The correlation between psychosis improvement and EP amplitudefintensity slope did not reach statistical significance (r = .66) but compared to the nonresponders, there was no overlap in this measure (Fisher's Exact Test, p < 0.05, I-tailed).
Blood levels were not always obtained on highest doses but each responder or worsener had a blood level equal to or higher than the responders, indicating that nonresponse was probably not secondary to not taking the drug, inadequate absorption or increased metabolism.
Various movement disorders were noted during the GHB trial and inc1uded extrapyramidal effects (cases 1,2, 3, 4, 6), akathisia (case 5), dyskinesia (cases land 6) and leg musc1e cramps (case 2). Strikingly, many of these movement disorders were noted following administration of probenecid for the LP. The patient who suffered musc1e cramps also had marked diuresis. Although GHB is administered as a salt and, therefore, the patient may lose potassium with the accompanying diuresis, neither this patient nor any other had abnormal potassium levels. Figure 2 and the following case reports describe the response of the patients to GHB. 
Results
Two patients improved, three did not change and two worsened (see Table 2 ). The median global psychosis rating for the seven patients was 5.8 (15-point scale) in the drug-free baseline period, 7.1 during maximum drug dose and 6.0 in the 
Case No. 1: Initial Worsening Followed by Antipsychotic Response
Patient DR has a three-year history of psychosis characterized by auditory and visual hallucinations. She previously had been treated with haloperidol without much improvement. The patient had two siblings with psychosis, one of whom had been diagnosed as having schizophrenia. Previously, she had experienced thought insertion, thought blocking and multiple voices commenting on her behavior. As noted in the graph, the patient was moderately psychotic before her GHB trial. On the second and third days of taking the drug, the patient had an increase in hallucinations. She showed confusion and reported feeling sedated. Seven days after GHB was started the nursing staff noted that the patient was definitely improved, compared to before beginning GHB. By the 20th day of GHB treatment the patient was functioning weil socially and psychotic symptomatology had disappeared. At this time she experienced four days of subtle oral-buccallingual dyskinesias, a symptom she had not shown previously.
She remained nonpsychotic for the remainder of her hospital stay.
Case No. 2: Partial Improvement with Remission Upon Withdrawal
Patient PD is a 34-year-old-female with a one-year history of psychosis and depression that began simultaneously following a hysterectomy. Her first hospitalization took place after she attempted to strangle her. daughter in response to a command from her hallucinations. She was treated with a number of drugs that included antipsychotics and antidepresants. She had some antipsychotic response to fluphenazine and thioridazine. The patient had two siblings diagnosed as schizophrenie. When she began the GHB trial, she suffered from nonaffective auditory and visual hallucinations, flattened affect, depressed feelings and paranoid delusions. Prior to the drug trial, the patient had paranoid ideas about research and had visul hallucinations of fires in her room. On the second day of the drug trial she had fewer hallucinations and found them less troubling (4 mg GHB/day). After nine days of GHB she had no hallucinations but experienced leg cramps following a probenecid LP. Two days prior to the end of the trial the patient said she was not depressed and did not hear voices. She experienced some hallucinations two days after GHB was discontinued but had no psychotic or depressive symptoms thereafter.
Case No. 3: Minimal Change in Psychosis
The patient is a 24-year-old male who suffered symptoms of paranoid, disorganized thinking that at times made bim incoherent with inappropriate affect for two years prior to admission. He was described as being a loner but had perforrned weil until his senior year of college when he developed persecutory delusions concerning homosexuals. He had one prior hospitalization during which he was treated with thioridazine, without much effect. He had a paternal aunt with schizophrenia. On admission the patient showed thought disorder, auditory and visual hallucinations, delusions and thought insertion. Before the drug trial, the patient changed little with the exception of becoming more suspicious. After one week on GHB he appeared more withdrawn and autistic. During probenecid pretreatment for bis LP he was noted to become even more autistic and to have marked increase in stereotypies and oral dyskinesias. The movement difficulties decreased after two days and were markedly better in two weeks. Clinically, the patient was somewhat better at the very end of his drug trial. When withdrawn from GHB, he worsened markedly, characterized by increased rituals and hallucinations.
Case No. 4: S/ight Worsening in Psychosis
The patient is a 26-year-old female with a three-year history of psychosis characterized by a well-organized paranoid delusion that the Mafia was going to kill her, marked ideas of reference and mild thought disorder. Prior to being admitted to NIMH, she had two episodes of running away from horne because of her fe ar of being killed by her father. She had two siblings with schizophrenia. On admission she exhibited thought disorder, poor insight, persecutory delusions and ideas of reference. Prior to her GHB trial the patient remained unchanged from her admission condition. On her first day of GHB she reported hearing voices in her head commenting on her sins. Two days later she heard the voices of the Mafia. Throughout her drug trial, she remained delusional and continued to feel depressed. Following probenecid LP the patient experienced muscle stiffness and bradykinesia. On the last two days of GHB, the patient began to include staff members into her hallucinations. Six days after the end of the drug trial the patient mentioned her delusions much less often and, for the frrst time, began to consider the possibility that her persecutory ideas might be delusions.
Case No. 5: Slight Worsening in Psychosis
The patient is a 23-year-old male who has been psychotic for seven years, characterized by thought blocking, delusions of being possessed by demons and immobilizing paranoia. Both his mother and maternal grandmother suffered from'schizophrenia. Prior to the GHB trial, the patient had auditory hallucinations and frightening delusions that led to bis keeping his back to the wall; however, he was able to participate in some milieu activities and individual therapy sessions. His illness had an undulating course with intensification of psychosis during the latter two-thirds of the study. He was noted to suffer from severe akathisia on a number of days throughout the trial (see Figure 2 ). This symptom disappeared in the placebo-replacerpent (postGHB) period.
Case No. 6: Minimal Change in Psychosis
This patient is a 23-year-old man who had the onset of psychosis at age 16. Three years before admission to our unit, he began receiving messages from television and acting on these messages. He was also experiencing auditory hallucinations, social withdrawal and thought disorder. The patient had been treated with fluphenazine without reduction of symptoms and had been steadily hospitalized. On admission he suffered from thought disorder, derealization and depersonalization. Four days prior to beginning the GHB drug trial, the patient was noted to be somewhat improved compared to admission. He had decreased ideas of reference and was more logical. On the first day of GHB his tbinking appeared slowed, bis talk was metaphorical and he had trouble relating to others. After three days ofGHB, the patient was described as having marked hallucinations, experiencing thought insertion and racing thoughts. Eight days after GHB was discontinued, the patient was described as considerably improved: he was less withdrawn, less referential and was not hallucinating as much as during the drug trial.
Case No. 7: Worsening with GHB
The patient is a 31-year-old fernale who had an eight-year bistory of chronic schizophrenie psychosis. She had been able to work with only occasional hospitalizations. Two years prior to admission to our study she continuously became more psychotic with her main symptoms being auditory hallucinations and delusions with religious content. Two days following the initiation of GHB, the patient becarne increasingly negativistic and psychotic. On the eighth day of the trial she was markedly psychotic. She showed pressure of speech, decreased sleep and was sexually provocative at which time she introduced herself to the other patients as the wife of her psychiatrist. This behaviour resembled her response to a double-blind infusion of 20 mg of amphetamine perforrned earlier in another study (van Kammen et al., submitted for publication). She had one period of approximately four days during which her psychosis level retumed to nearly pretriallevels but this trend abruptly ended by a switch back to the excited behavior (as seen during the last week of GHB treatment). Interestingly, five days after GHB was stopped, the patient remarked, "I'm feeling a lot better" This was corroborated by the double-blind observations of the staff, who noted she appeared to be less psychotic.
Discussion
This is the first double-blind, placebo-replacement investigation of the effects of GHB on the symptoms of schizophrenia. Two of the seven patients in the study improved while they were taking the drug. The patients who improved received ratings in the nonpsychotic range. Both responders had been observed to have stable psychopathology for over two months, improved more than with previous treatments and remained nonpsychotic for some time following the drug trial. Although this may raise some questions about GHB's being the causal agent of the improvement, other treatments of schizophrenia, such as neuroleptics, are not followed by relapse immediatelyon withdrawal. However, several patients experienced exacerbation of their psychosis sometimes associated with increases in the dose ofGHB.
Despite the small sampie size of this study, the double-blind design in which the patient serves as his own control makes the response of the two patients who responded interesting, especially because of current forrnulations of the heterogeneity in the etiology of schizophrenia (Buchsbaum and Rieder, 1979) . GHB, whether it acts independently or through a GABAergic mechanism, decreases the firing-rate of dopaminergic neurons (Walters et al., 1972; Olpe and Koe/la, 1979; Roth et al., 1973; . In addition, GHB appears to be active particularly in the mesolimbic DA tracts (Fuxe et al., 1977) . It is conceivable that the responders were patients with a heightened dopaminergic tone. The nonresponders may have been a group in which a different mechanism led to their psychosis. High preGHB CSF HVA (an indicator of DA turnover) was associated with a decrease in psychosis. In addition, probeneeid {P's were not helpful in deterrnining how GHB interacted with DA in a clinically relevant way. HVA values increased in one responder but decreased in the other; the same was true for the two nonresponders who had probenecid {P's.
It is of interest that the two responders had both low MAO activity and an augmenting response on the EP. This combination has been predictive of risk for suicidal attempts in normal and psychiatrie populations Buchsbaum and Rieder, 1979) and as apredictor of risk for affective and other symptoms in volunteer populations (Haier et al., 1979) .
To enhance GHB levels, probenecid could be administered simultaneously. As the authors have noted, a number of patients develop motor difficulties after taking probenecid while on GHB. The possibility exists that probenecid decreases the urinary excretion of GHB and also interferes with the transport out of the CSF. If this could be confrrmed, a lower dose of GHB could be given with probenecid and a more stable blood level maintained.
The interaction of GHB with neuroleptics was not studied. This possibility has been suggested by other workers and, in light of the results of this study showing two responders to GHB alone, should be investigated.
Finally, in this study GHB seemed to be an antipsychotic agent in two patients who had not previously shown a satisfactory response to antipsychotic drugs. Further study is warranted: patients who are unresponsive to neuroleptics, have high CSF HVA levels and are augmenters on the EP with low platelet MAO activity may be potentially successful candidates.
